Capricor Therapeutics (CAPR) Operating Expenses (2010 - 2026)

Capricor Therapeutics' Operating Expenses history runs 17 years deep, the most recent figure standing at $36.8 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 47.19% year-over-year to $36.8 million; the TTM figure through Mar 2026 stood at $119.9 million (up 60.67% YoY), while the FY2025 annual figure was $108.1 million, up 66.8% from the prior year.
• Operating Expenses was $36.8 million for Q1 2026 at Capricor Therapeutics, up from $29.2 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $36.8 million in Q1 2026 to a low of $7.3 million in Q2 2022.
• Historically, Operating Expenses has averaged $17.1 million across 5 years, with a median of $15.2 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Operating Expenses surged 87.03% in 2022, then grew 17.02% in 2024.
• A 5-year view of Operating Expenses shows it stood at $9.0 million in 2022, then surged by 48.12% to $13.4 million in 2023, then surged by 40.82% to $18.8 million in 2024, then surged by 54.86% to $29.2 million in 2025, then increased by 26.12% to $36.8 million in 2026.
• The last three Operating Expenses figures came in at $36.8 million (Q1 2026), $29.2 million (Q4 2025), and $26.3 million (Q3 2025), per Business Quant data.